Welcome to our dedicated page for Jazz Pharmaceuticals Plc SEC filings (Ticker: JAZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Jazz Pharmaceuticals plc (Nasdaq: JAZZ) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory disclosures, alongside AI-assisted summaries to help interpret complex documents. Jazz, an Ireland-incorporated global biopharma company, files current and periodic reports as an issuer with ordinary shares listed on The Nasdaq Stock Market LLC under the symbol JAZZ.
Investors and researchers can review Form 8-K filings that report material events, including clinical trial milestones for products such as Ziihera (zanidatamab-hrii), financial results for specific quarters, executive and board changes, and legal settlements related to its sleep disorder and epilepsy franchises. These current reports often reference accompanying press releases that provide additional narrative detail on oncology and neuroscience developments.
Through this page, users can also locate references to quarterly and annual reports (Forms 10-Q and 10-K when available), which typically contain broader discussions of Jazz’s business, risk factors, pipeline, marketed medicines and financial condition. In addition, proxy materials and shareholder meeting results, such as votes on director elections and auditor appointments, are accessible for those tracking governance matters.
Stock Titan’s AI tools are designed to highlight key points from lengthy filings, helping users quickly identify sections related to oncology programs, neuroscience assets, royalty and settlement agreements, or capital markets activity. Where applicable, investors can also review insider-related filings such as Forms 3, 4 and 5 to monitor transactions in JAZZ ordinary shares by directors and officers, as reported to the SEC.
By combining real-time EDGAR updates with AI-generated overviews, this page offers a practical way to follow how Jazz Pharmaceuticals documents its clinical progress, corporate actions and financial reporting obligations in the U.S. regulatory framework.
Jazz Pharmaceuticals director Bruce C. Cozadd reported a tax-related share disposition. On the vesting of previously granted restricted stock units, 15,114 Ordinary Shares were withheld at $188.69 per share to satisfy tax obligations, reducing his directly held stake to 390,682 Ordinary Shares. This Form 4 reflects a tax-withholding transaction rather than an open-market trade.
Jazz Pharmaceuticals plc Executive Vice President and Chief Financial Officer Philip L. Johnson reported a tax-related share disposition. On March 5, 2026, 2,615 ordinary shares were withheld at $188.69 per share to cover tax obligations from the vesting of previously granted restricted stock units. After this withholding, he directly held 59,608 ordinary shares.
Jazz Pharmaceuticals plc SVP, Technical Operations Mary Elizabeth Henderson reported a tax-related share disposition. On March 5, 2026, she disposed of 1,394 ordinary shares to satisfy tax obligations from vesting restricted stock units, at a weighted average price of $186.747 per share.
The shares were sold in multiple transactions at prices ranging from $186.1633 to $186.7558. After these transactions, Henderson directly owned 27,334 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals plc executive reports tax-related share disposition. EVP and Chief Commercial Officer Samantha Pearce had 2,503 Ordinary Shares withheld at $188.69 per share to satisfy tax obligations from the vesting of previously granted restricted stock units. After this tax-withholding transaction, she directly owns 50,272 Ordinary Shares.
Jazz Pharmaceuticals EVP Robert Iannone, Global Head of R&D and CMO, reported a tax-related share disposition. On March 5, 2026, 6,209 ordinary shares were withheld at a price of 188.69 per share to satisfy tax obligations from the vesting of previously granted restricted stock units.
Following this tax-withholding disposition, Iannone directly holds 88,871 ordinary shares of Jazz Pharmaceuticals. This transaction reflects administrative share withholding rather than an open-market purchase or sale.
Jazz Pharmaceuticals SVP and Chief Accounting Officer Patricia Carr reported two share dispositions. On March 9, 2026, she completed an open-market sale of 1,287 ordinary shares at a weighted average price of $182.94, leaving 6,512 shares directly owned afterward.
On March 5, 2026, she disposed of 1,436 ordinary shares at $186.7723 per share to satisfy tax obligations arising from the vesting of previously granted restricted stock units, resulting in 7,799 shares directly owned following that transaction.
Jazz Pharmaceuticals plc President & CEO Renee D. Gala reported a tax-related share transaction. On March 5, 2026, 7,065 ordinary shares were disposed of at $188.69 per share to satisfy tax obligations from vesting restricted stock units. After this withholding transaction, she directly owned 152,630 ordinary shares.
Jazz Pharmaceuticals plc executive Neena M. Patil, EVP & Chief Legal Officer, reported a tax-related share disposition. On March 5, 2026, 5,000 Ordinary Shares of Jazz were withheld at $188.69 per share to satisfy tax obligations from the vesting of previously granted restricted stock units. This was recorded as a tax-withholding disposition rather than an open-market sale, and Patil’s directly held stake after the transaction was 53,818 Ordinary Shares.
Patricia Carr submitted a Form 144 notice reporting proposed sales of Common stock and recent transactions. The filing lists restricted stock items of 342, 294, 353 and 298 shares dated 03/05/2026. It also records sales during the past three months: 1,436 shares for $268,544.91 on 03/05/2026, 1,117 shares for $213,243.45 on 02/27/2026, and 1,253 shares for $243,810.00 on 02/26/2026.
JAZZ filed a Form 144 reporting proposed and recent transactions in common stock. The filing lists restricted stock vesting dated 03/05/2026 under "Issuer" for compensation. It also lists securities sold in the past three months by Patricia Carr on 12/05/2025, 02/26/2026, and 02/27/2026 with numeric entries 4660/797783.00, 1253/243810.00, and 1117/213243.00 respectively.